Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.460
-0.080 (-5.19%)
Dec 5, 2025, 4:00 PM EST - Market closed
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Prelude Therapeutics stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 173.97% from the current stock price of 1.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 23, 2025.
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +242.47% | Sep 23, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +105.48% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +242.47% | May 5, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $4 | Buy | Reiterates | $4 | +173.97% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +242.47% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
n/a
from 7.00M
Revenue Next Year
51.00M
EPS This Year
-1.27
from -1.68
EPS Next Year
-1.07
from -1.27
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 105.0M | ||||
| Avg | n/a | 51.0M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.29 | -1.10 | |
| Avg | -1.27 | -1.07 | |
| Low | -1.24 | -1.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.